Sweta Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sweta Gupta has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Amy D. Shapiro
Indiana Hemophilia and Thrombosis Center, Indianapolis, IN
3 shared publications A. D. Shapiro
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, IN, USA
2 shared publicationsAmy D. Shapiro
Department of Pediatric Hematology, Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA
2 shared publicationsAmy Shapiro
Indiana Hemophilia and Thrombosis Center Inc
2 shared publicationsEric E. Tibesar
Department of Pediatric Gastroenterology Peyton Manning Children's hospital Ascension Health Indianapolis Indiana USA
2 shared publicationsJ. Michael Soucie
National Center on Birth Defects and Developmental Disabilities Division of Blood Disorders Centers for Disease Control and Prevention Atlanta Georgia
2 shared publications
Latest Publications
- Open Access
- 28 November 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102646
Acquired factor V inhibitor in a case of pediatric venous thrombosis
- 28 November 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102646
Open AccessAcquired factor V inhibitor in a case of pediatric venous thrombosis
- 1 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6661) , eadh5207
Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes
Apolipoprotein B (apoB)–lipoproteins initiate and promote atherosclerotic cardiovascular disease. Plasma tissue plasminogen activator (tPA) activity is negatively associated with atherogenic apoB-lipoprotein cholesterol levels in humans, but the mechanisms are unknown. We found that tPA, partially through the lysine-binding site on its Kringle 2 domain, binds to the N terminus of apoB, blocking the interaction between apoB and microsomal triglyceride transfer protein (MTP) in hepatocytes, thereby reducing very-low-density lipoprotein (VLDL) assembly and plasma apoB-lipoprotein cholesterol levels. Plasminogen activator inhibitor 1 (PAI-1) sequesters tPA away from apoB and increases VLDL assembly. Humans with PAI-1 deficiency have smaller VLDL particles and lower plasma levels of apoB-lipoprotein cholesterol. These results suggest a mechanism that fine-tunes VLDL assembly by intracellular interactions among tPA, PAI-1, and apoB in hepatocytes.
- 1 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6661) , eadh5207
Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes
Apolipoprotein B (apoB)–lipoproteins initiate and promote atherosclerotic cardiovascular disease. Plasma tissue plasminogen activator (tPA) activity is negatively associated with atherogenic apoB-lipoprotein cholesterol levels in humans, but the mechanisms are unknown. We found that tPA, partially through the lysine-binding site on its Kringle 2 domain, binds to the N terminus of apoB, blocking the interaction between apoB and microsomal triglyceride transfer protein (MTP) in hepatocytes, thereby reducing very-low-density lipoprotein (VLDL) assembly and plasma apoB-lipoprotein cholesterol levels. Plasminogen activator inhibitor 1 (PAI-1) sequesters tPA away from apoB and increases VLDL assembly. Humans with PAI-1 deficiency have smaller VLDL particles and lower plasma levels of apoB-lipoprotein cholesterol. These results suggest a mechanism that fine-tunes VLDL assembly by intracellular interactions among tPA, PAI-1, and apoB in hepatocytes.
- 21 March 2023
- Published by Wiley in Haemophilia
- Vol. 29 (3) , 928-930
Severe FVII deficiency presenting with heterotopic gastric mucosa: hoofbeats may be a zebra
- 21 March 2023
- Published by Wiley in Haemophilia
- Vol. 29 (3) , 928-930
Severe FVII deficiency presenting with heterotopic gastric mucosa: hoofbeats may be a zebra
- Open Access
- 4 January 2023
- Published by Wiley
Severe FVII deficiency presenting with Heterotopic gastric mucosa: Hoofbeats may be a zebra
Gastrointestinal (GI) tract bleeding can present as symptomatic anemia in children. This presentation warrants evaluation for GI tract pathology and consideration of coagulation assays to rule out an underlying bleeding diathesis. A male child was diagnosed with a rare bleeding disorder, severe (<1%) factor VII (FVII) deficiency during evaluation of severe iron deficiency anemia (IDA) secondary to recurrent GI bleeding. Despite adequate prophylaxis for the underlying bleeding disorder, continued GI bleeding and anemia led to further evaluation and identification of a rare small intestinal tract lesion, heterotopic gastric mucosa (HGM). Surgical treatment of the lesion resulted in complete symptom resolution and abated the need for prophylactic factor replacement therapy.
- 4 January 2023
- Published by Wiley
Open AccessSevere FVII deficiency presenting with Heterotopic gastric mucosa: Hoofbeats may be a zebra
Gastrointestinal (GI) tract bleeding can present as symptomatic anemia in children. This presentation warrants evaluation for GI tract pathology and consideration of coagulation assays to rule out an underlying bleeding diathesis. A male child was diagnosed with a rare bleeding disorder, severe (<1%) factor VII (FVII) deficiency during evaluation of severe iron deficiency anemia (IDA) secondary to recurrent GI bleeding. Despite adequate prophylaxis for the underlying bleeding disorder, continued GI bleeding and anemia led to further evaluation and identification of a rare small intestinal tract lesion, heterotopic gastric mucosa (HGM). Surgical treatment of the lesion resulted in complete symptom resolution and abated the need for prophylactic factor replacement therapy.
- Open Access
- 28 July 2021
- Published by Medip Academy in International Surgery Journal
- Vol. 8 (8) , 2484-2487
En-block resection of a giant retroperitoneal lipoma presented as huge abdominal swelling: a case report
Retroperitoneal lipomas are an extremely rare entity with only less than 20 cases described in the literature so far. They can attain immoderate size due to space provided in the retroperitoneum and cause abdominal symptoms like abdominal pain, swelling and obstipation due to mass effect. Case presented here as of 53 years old male with complaint of abdominal swelling that had been progressive for the last 1 year. On computed tomography (CT) it revealed giant retroperitoneal mass? liposarcoma? occupying the space immensely. Intraoperatively, two giant retroperitoneal tumours were found which did not show any features of infiltration to nearby structures, therefore the sole tumour annihilation was achieved, which was diagnosed as benign lipoma on histopathology report later. The most important differential diagnosis is the well differentiated liposarcoma, which could only be confirmed after resection and histopathological assessment. Retroperitoneal lipomas are clearly not distinguishable from well differentiated liposarcomas on CT guided and USG guided biopsy and thus it could be misleading. Hence surgical resection with negative margins along with histopathological confirmation is treatment of choice with regular follow up to diagnose early recurrence if any.
- 28 July 2021
- Published by Medip Academy in International Surgery Journal
- Vol. 8 (8) , 2484-2487
Open AccessEn-block resection of a giant retroperitoneal lipoma presented as huge abdominal swelling: a case report
Retroperitoneal lipomas are an extremely rare entity with only less than 20 cases described in the literature so far. They can attain immoderate size due to space provided in the retroperitoneum and cause abdominal symptoms like abdominal pain, swelling and obstipation due to mass effect. Case presented here as of 53 years old male with complaint of abdominal swelling that had been progressive for the last 1 year. On computed tomography (CT) it revealed giant retroperitoneal mass? liposarcoma? occupying the space immensely. Intraoperatively, two giant retroperitoneal tumours were found which did not show any features of infiltration to nearby structures, therefore the sole tumour annihilation was achieved, which was diagnosed as benign lipoma on histopathology report later. The most important differential diagnosis is the well differentiated liposarcoma, which could only be confirmed after resection and histopathological assessment. Retroperitoneal lipomas are clearly not distinguishable from well differentiated liposarcomas on CT guided and USG guided biopsy and thus it could be misleading. Hence surgical resection with negative margins along with histopathological confirmation is treatment of choice with regular follow up to diagnose early recurrence if any.
- 17 May 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (9) , 1022-1029
Laboratory misdiagnosis of von Willebrand disease in post‐menarchal females: A multi‐center study
Increased awareness of von Willebrand Disease (VWD) has led to more frequent diagnostic laboratory testing, which insurers often dictate be performed at a facility with off‐site laboratory processing, instead of a coagulation facility with onsite processing. Off‐site processing is more prone to preanalytical variables causing falsely low levels of von Willebrand Factor (VWF) due to the additional transport required. Our aim was to determine the percentage of discordance between off‐site and onsite specimen processing for VWD in this multicenter, retrospective study. We enrolled females aged 12 to 50 years who had off‐site specimen processing for VWF assays, and repeat testing performed at a consulting institution with onsite coagulation phlebotomy and processing. A total of 263 females from 17 institutions were included in the analysis. There were 251 subjects with both off‐site and onsite VWF antigen (VWF:Ag) processing with 96 (38%) being low off‐site and 56 (22%) low onsite; 223 subjects had VWF ristocetin co‐factor (VWF:RCo), 122 (55%) were low off‐site and 71 (32%) were low onsite. Similarly, 229 subjects had a Factor VIII (FVIII) assay, and 67 (29%) were low off‐site with less than half, 29 (13%) confirmed low with onsite processing. Higher proportions of patients demonstrated low VWF:Ag, VWF:RCo, and/or FVIII with off‐site processing compared to onsite (McNemarʼs test P‐value <.0005, for all assays). These results emphasize the need to decrease delays from sample procurement to processing for VWF assays. The VWF assays should ideally be collected and processed at the same site under the guidance of a hematologist.
- 17 May 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (9) , 1022-1029
Laboratory misdiagnosis of von Willebrand disease in post‐menarchal females: A multi‐center study
Increased awareness of von Willebrand Disease (VWD) has led to more frequent diagnostic laboratory testing, which insurers often dictate be performed at a facility with off‐site laboratory processing, instead of a coagulation facility with onsite processing. Off‐site processing is more prone to preanalytical variables causing falsely low levels of von Willebrand Factor (VWF) due to the additional transport required. Our aim was to determine the percentage of discordance between off‐site and onsite specimen processing for VWD in this multicenter, retrospective study. We enrolled females aged 12 to 50 years who had off‐site specimen processing for VWF assays, and repeat testing performed at a consulting institution with onsite coagulation phlebotomy and processing. A total of 263 females from 17 institutions were included in the analysis. There were 251 subjects with both off‐site and onsite VWF antigen (VWF:Ag) processing with 96 (38%) being low off‐site and 56 (22%) low onsite; 223 subjects had VWF ristocetin co‐factor (VWF:RCo), 122 (55%) were low off‐site and 71 (32%) were low onsite. Similarly, 229 subjects had a Factor VIII (FVIII) assay, and 67 (29%) were low off‐site with less than half, 29 (13%) confirmed low with onsite processing. Higher proportions of patients demonstrated low VWF:Ag, VWF:RCo, and/or FVIII with off‐site processing compared to onsite (McNemarʼs test P‐value <.0005, for all assays). These results emphasize the need to decrease delays from sample procurement to processing for VWF assays. The VWF assays should ideally be collected and processed at the same site under the guidance of a hematologist.
- 1 October 2019
- Published by Elsevier in Thrombosis Research
- Vol. 182, 43-50
Mathematical model of thrombin generation and bleeding phenotype in Amish carriers of Factor IX:C deficiency vs. controls
- 1 October 2019
- Published by Elsevier in Thrombosis Research
- Vol. 182, 43-50
Mathematical model of thrombin generation and bleeding phenotype in Amish carriers of Factor IX:C deficiency vs. controls
- 11 September 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 1045-1050
Potential of the Community Counts registry to characterize rare bleeding disorders
Introduction Rare bleeding disorders (RBDs) comprise of heterogeneous coagulation factor deficiencies and platelet disorders that are underreported worldwide. Aim First report on RBD data from United States haemophilia treatment center network (USHTCN). Methods A national surveillance system for the federally recognized USHTCN developed in collaboration with the Centers for Disease Control and Prevention (CDC) and American Thrombosis and Haemostasis Network (ATHN) was queried for patients with RBDs. Patient counts were extracted from the HTC Population Profile (HTC PP) component including limited data on patients followed through the USHTCN, and from the Registry component, including patient authorized, detailed clinical data. The prevalence of RBDs in the United States was estimated based on the HTC PP data and compared to the expected national prevalence based on data extrapolated from Orphanet, an international registry. Results Based on the estimated prevalence of RBD in the overall 2017 US population, the cases in the HTC network were lower than expected for FI, FII, FX, and FV + FVIII deficiencies by 36%, 61%, 75% and 94%, respectively, and higher than expected for FXIII, FV, FVII, and FXI deficiencies by 7%, 14%, 33% and 185%, respectively. The proportion of RBD patients reported in the HTC PP, enrolled in the Registry, was 10.8%. Conclusions There is a clear need to identify individuals with RBDs who could benefit from the comprehensive care provided in the USHTCN. In addition, increased enrolment of people with all RBDs in the Registry is needed to improve knowledge of treatment outcomes of patients with RBDs in the United States.
- 11 September 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 1045-1050
Potential of the Community Counts registry to characterize rare bleeding disorders
Introduction Rare bleeding disorders (RBDs) comprise of heterogeneous coagulation factor deficiencies and platelet disorders that are underreported worldwide. Aim First report on RBD data from United States haemophilia treatment center network (USHTCN). Methods A national surveillance system for the federally recognized USHTCN developed in collaboration with the Centers for Disease Control and Prevention (CDC) and American Thrombosis and Haemostasis Network (ATHN) was queried for patients with RBDs. Patient counts were extracted from the HTC Population Profile (HTC PP) component including limited data on patients followed through the USHTCN, and from the Registry component, including patient authorized, detailed clinical data. The prevalence of RBDs in the United States was estimated based on the HTC PP data and compared to the expected national prevalence based on data extrapolated from Orphanet, an international registry. Results Based on the estimated prevalence of RBD in the overall 2017 US population, the cases in the HTC network were lower than expected for FI, FII, FX, and FV + FVIII deficiencies by 36%, 61%, 75% and 94%, respectively, and higher than expected for FXIII, FV, FVII, and FXI deficiencies by 7%, 14%, 33% and 185%, respectively. The proportion of RBD patients reported in the HTC PP, enrolled in the Registry, was 10.8%. Conclusions There is a clear need to identify individuals with RBDs who could benefit from the comprehensive care provided in the USHTCN. In addition, increased enrolment of people with all RBDs in the Registry is needed to improve knowledge of treatment outcomes of patients with RBDs in the United States.
- Open Access
- 30 August 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 1073-1082
Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
Introduction: Deficiencies of plasminogen and plasminogen activator inhibitor type 1 (PAI‐1) are rare disorders of fibrinolysis. Current laboratory assays for analysis of activity of plasminogen and PAI‐1 do not provide an accurate correlation with clinical phenotype.Methods: The Nijmegen Hemostasis Assay (NHA) was used to simultaneously measure thrombin and plasmin generation in 5 patients with plasminogen deficiency (PLGD) and 10 patients with complete PAI‐1 deficiency. Parameters analysed included: lag time ratio, thrombin peak time ratio, thrombin peak height, thrombin potential (AUC), fibrin lysis time, plasmin peak height and plasmin potential. Parameters were expressed as a percentage compared to a reference value of 53 healthy normal controls.Results: Patients with PLGD demonstrated a short lag time and thrombin peak time, with normal thrombin peak height but an increased AUC. Plasmin generation was able to be detected in only one (23% plasminogen activity) of the five PLGD patients. All ten PAI‐1 deficient patients demonstrated a short lag and thrombin peak time, low thrombin peak height with normal AUC. Plasmin generation revealed an increased plasmin peak and plasmin potential; interestingly, there was a large variation between individual patients despite all patients having the same homozygous defect.Conclusion: Patients with either PLGD or PAI‐1 deficiency show distinct abnormalities in plasmin and thrombin generation in the NHA. The differences observed in the propagation phase of thrombin generation may be explained by plasmin generation. These results suggest that disorders of fibrinolysis also influence coagulation and a global assay measuring both activities may better correlate with clinical outcome.
- 30 August 2019
- Published by Wiley in Haemophilia
- Vol. 25 (6) , 1073-1082
Open AccessThrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
Introduction: Deficiencies of plasminogen and plasminogen activator inhibitor type 1 (PAI‐1) are rare disorders of fibrinolysis. Current laboratory assays for analysis of activity of plasminogen and PAI‐1 do not provide an accurate correlation with clinical phenotype.Methods: The Nijmegen Hemostasis Assay (NHA) was used to simultaneously measure thrombin and plasmin generation in 5 patients with plasminogen deficiency (PLGD) and 10 patients with complete PAI‐1 deficiency. Parameters analysed included: lag time ratio, thrombin peak time ratio, thrombin peak height, thrombin potential (AUC), fibrin lysis time, plasmin peak height and plasmin potential. Parameters were expressed as a percentage compared to a reference value of 53 healthy normal controls.Results: Patients with PLGD demonstrated a short lag time and thrombin peak time, with normal thrombin peak height but an increased AUC. Plasmin generation was able to be detected in only one (23% plasminogen activity) of the five PLGD patients. All ten PAI‐1 deficient patients demonstrated a short lag and thrombin peak time, low thrombin peak height with normal AUC. Plasmin generation revealed an increased plasmin peak and plasmin potential; interestingly, there was a large variation between individual patients despite all patients having the same homozygous defect.Conclusion: Patients with either PLGD or PAI‐1 deficiency show distinct abnormalities in plasmin and thrombin generation in the NHA. The differences observed in the propagation phase of thrombin generation may be explained by plasmin generation. These results suggest that disorders of fibrinolysis also influence coagulation and a global assay measuring both activities may better correlate with clinical outcome.
- 21 May 2018
- Published by Wiley in Haemophilia
- Vol. 24 (S6) , 76-86
Optimizing bleed prevention throughout the lifespan: Womb to Tomb
The focus of care providers, patients and families is the ability to tailor care for persons with haemophilia (PWH) across the lifespan. Care requires knowledge of the bleeding disorder and age‐related complications, risk of therapeutic interventions, and evaluation of individual characteristics that contribute to outcomes. The ultimate goal is to live a normal life without the burden of bleeding, for PWH and carriers. A wide range of therapeutic options is required to achieve personalized care. Over the last decade, substantial therapeutic advantages have been achieved in the treatment of haemophilia that include the development of a robust array of factor concentrates, novel haemostatic agents, and increased knowledge and awareness of disease associated outcomes and risk factors. Significant strides on the road to accessible gene therapy have been realized. This increased range of therapeutic modalities provides options for development and implementation of care plans for each patient at each stage of life that are more flexible compared to prior care regimens. Paradigms for management of haemophilia are changing. As a community, we must work together to use these resources wisely, to learn from outcomes with new therapies and diagnostic tools, to assure all patients can achieve improved care and outcomes regardless of disease state or country of origin.
- 21 May 2018
- Published by Wiley in Haemophilia
- Vol. 24 (S6) , 76-86
Optimizing bleed prevention throughout the lifespan: Womb to Tomb
The focus of care providers, patients and families is the ability to tailor care for persons with haemophilia (PWH) across the lifespan. Care requires knowledge of the bleeding disorder and age‐related complications, risk of therapeutic interventions, and evaluation of individual characteristics that contribute to outcomes. The ultimate goal is to live a normal life without the burden of bleeding, for PWH and carriers. A wide range of therapeutic options is required to achieve personalized care. Over the last decade, substantial therapeutic advantages have been achieved in the treatment of haemophilia that include the development of a robust array of factor concentrates, novel haemostatic agents, and increased knowledge and awareness of disease associated outcomes and risk factors. Significant strides on the road to accessible gene therapy have been realized. This increased range of therapeutic modalities provides options for development and implementation of care plans for each patient at each stage of life that are more flexible compared to prior care regimens. Paradigms for management of haemophilia are changing. As a community, we must work together to use these resources wisely, to learn from outcomes with new therapies and diagnostic tools, to assure all patients can achieve improved care and outcomes regardless of disease state or country of origin.